Indivior PLC (NASDAQ:INDV – Get Free Report)’s stock price fell 5.3% during trading on Monday . The company traded as low as $37.86 and last traded at $37.9030. 1,329,739 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 2,133,043 shares. The stock had previously closed at $40.01.
Analyst Upgrades and Downgrades
Several research firms have weighed in on INDV. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings raised Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th. Finally, Barclays assumed coverage on Indivior in a report on Thursday, June 18th. They issued an “overweight” rating and a $46.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.67.
Indivior Stock Down 5.3%
Indivior (NASDAQ:INDV – Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $343.00 million for the quarter. Sell-side analysts predict that Indivior PLC will post 4.05 earnings per share for the current year.
Insiders Place Their Bets
In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the transaction, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the transaction, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. The trade was a 11.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its holdings in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after buying an additional 1,299,425 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in shares of Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after buying an additional 3,201,639 shares during the period. Vanguard Group Inc. increased its stake in shares of Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after buying an additional 2,008,078 shares during the period. State Street Corp increased its stake in shares of Indivior by 65.5% during the fourth quarter. State Street Corp now owns 4,659,281 shares of the company’s stock valued at $167,175,000 after buying an additional 1,844,532 shares during the period. Finally, Rubric Capital Management LP raised its holdings in shares of Indivior by 31.6% during the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after acquiring an additional 1,117,140 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.
About Indivior
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Featured Articles
- Five stocks we like better than Indivior
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
